+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

S

Actively Recruiting

Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.

Age: 18Years - 100YearsAll Genders
33 locations
S

Actively Recruiting

Researchers are investigating the effects of transcranial electrical stimulation tES, which includes transcranial direct current stimulation tDCS and transcranial alternating current stimulation tACS, combined with conventional physical therapy and cognitive-motor dual-task gait training in individuals who have experienced a stroke. The study focuses on those in the sub-acute phase at least 2 weeks after stroke onset up to chronic phase within 5 years post-stroke. The goal is to understand how these treatments affect brain activity, spinal motoneuron excitability, cognition, and motor performance, potentially improving rehabilitation approaches for stroke survivors. Participants will be randomly assigned to one of three groups active tDCS, active tACS, or sham stimulation, each followed by conventional physical therapy and cognitive-motor dual-task gait training. Each session includes 20 minutes of the assigned brain stimulation, 1 hour of physical therapy, and 30 minutes of gait training, with a total of 12 sessions over 4 weeks 3 sessions per week. Electrodes are placed over the affected side of the brains motor cortex, and stimulation parameters differ between tDCS and tACS to target neural plasticity and brain wave activity. Throughout the study, participants will undergo assessments at baseline, immediately post-intervention, and at 1- and 3-month follow-ups. These evaluations include brain activity measured by EEG, spinal motoneuron excitability via H-reflex tests, cognitive tests like the Montreal Cognitive Assessment and Stroop test, and motor function tests such as the Fugl-Meyer assessment and Timed Up and Go test. Researchers will also monitor walking performance under dual-task conditions to assess cognitive-motor interference, gathering a comprehensive picture of treatment effects and safety over time.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
1 location
O

Actively Recruiting

Healthy Volunteer

Researchers are investigating long-term iron absorption, loss, and overall iron balance in overweight or obese middle-aged Thai women compared with normal-weight women. This study addresses the concern that chronic low-grade inflammation common in obesity may affect how iron is absorbed and used in the body, potentially leading to iron deficiency and anemia. The study is a longitudinal observational trial conducted to understand these effects better and to inform health policies and programs for improving iron status and outcomes. The study involves 64 women aged 40 to 50 years, split evenly between overweightobese and normal-weight groups. Participants undergo an initial screening visit with health assessments, blood tests, and a pregnancy test. Eligible women then consume a 15 mg iron isotope solution with vitamin C, followed by a year-long monitoring period with monthly records of illness and menstrual data. Several follow-up visits occur over 24 weeks for blood tests, body measurements, dietary recalls, and questionnaires to track iron absorption and loss. Participants will engage in multiple visits for blood collection and health measurements, including weight, body composition, blood pressure, and dietary assessments. Laboratory tests measure various iron-related markers, inflammation, glucose, lipids, and isotopic enrichment to analyze iron metabolism over time. The primary outcomes focus on mean long-term iron absorption, iron loss, and iron gain after one year and during the follow-up period. The study also tracks secondary outcomes like nutrient intake, body mass index, and biochemical parameters, supporting a comprehensive understanding of iron status in these women.

Age: 40Years - 50YearsFEMALE
1 location
I

Actively Recruiting

Researchers are investigating the best way to start peritoneal dialysis PD for patients with kidney failure, a condition that is fatal without dialysis. This international, multicenter trial compares the usual full dose PD, given continuously 247, with a lower starting dose that increases over time. The study aims to see if starting with less intensive PD can preserve quality of life, reduce treatment burden, be safe, more cost-effective, and better for the environment. Participants are randomized to one of two groups incremental PD, which starts with fewer exchanges per week and increases only if needed, or full dose PD, which involves daily treatment 24 hours a day. The incremental group receives up to 14 exchanges per week for continuous ambulatory PD or up to 21 for automated PD without a daytime dwell, while the full dose group receives a full 247 regimen. The study is open-label and adaptive, designed with input from patients who have experience with PD. During the trial, participants will have regular assessments including quality of life measures up to 6 months and monitoring of kidney function, adverse events, hospitalizations, and complications up to 18 months. The research team will track symptom burden, survival, cardiovascular events, and infections related to PD. The study is planned to run until September 2029, with ongoing safety and effectiveness evaluations throughout.

Age: 18Years +All GendersPhase Not Applicable
14 locations